<DOC>
	<DOCNO>NCT01976078</DOCNO>
	<brief_summary>The death rate child invasive fungal infection call aspergillosis 50 % . Voriconazole first-line therapy infection . In previous publication investigator show highly significant relationship voriconazole plasma concentration survival . However , voriconazole dose currently poorly establish , plasma drug exposure vary child 400 % , even intravenous dose . The objective study investigate reason variability voriconazole pharmacokinetics ( PK ) .In two study , investigator enroll 80 children/adolescents receive oral intravenous voriconazole , divide age 2 year ( n=15 ) , 2-18 year ( n=65 ) . From patient investigator collect follow : 1 ) blood sample detection several genetic change know affect drug metabolize enzyme ( DME ) activity ; 2 ) 9 blood sample voriconazole dose measurement voriconazole ( `` PK sampling '' ) ; 3 ) follow-up sample PK sample visit necessary adjust dose voriconazole concentration blood satisfactory ( know therapeutic drug monitoring TDM ) . At time voriconazole dose prior PK sampling , also give single IV oral ( correspond route voriconazole administration ) low dos esomeprazole ( antacid ) , midazolam ( sedative ) , ranitidine ( antacid ) cocktail test probe DME activity . All medication use commonly child already . The investigator estimate DME activity phenotype use ratio probe drug metabolite parent drug concentration , simultaneously quantify amount DME genetic material ( mRNA ) protein white blood cell . The investigator test association DME activity , mRNA , protein , voriconazole PK , age , sex , degree illness . The investigator also use computer program integrate data develop comprehensive model predict blood concentration voriconazole child age , well assist physician pharmacist dose voriconazole accurately.The total study duration subject TDM follow visit , generally one week .</brief_summary>
	<brief_title>Development Voriconazole Pharmacokinetics Metabolism Children Adolescents</brief_title>
	<detailed_description />
	<mesh_term>Voriconazole</mesh_term>
	<mesh_term>Esomeprazole</mesh_term>
	<mesh_term>Ranitidine</mesh_term>
	<mesh_term>Ranitidine bismuth citrate</mesh_term>
	<mesh_term>Midazolam</mesh_term>
	<criteria>1 . Participants enrol 18th birthday . 2 . Participant/parent/legal guardian must able willing provide sign informed consent . 3 . Laboratory value obtain within 7 day prior study entry ( obtained clinical purpose ) 1 . Hemoglobin ≥ 7.0 g/dL ( transfusion dependence acceptable ) 2 . Aspartate aminotransferase ( AST ) ( SGOT ) , alanine aminotransferase ( ALT ) ( SGPT ) , total bilirubin ≤ 5 X upper limit ageappropriate normal ( ULN ) 3 . Serum creatinine ≤ 3 X ULN 1 . Pregnancy 2 . Active substance abuse psychiatric illness would prevent adherence study protocol . Investigators record information screen log , information obtain exist document medical record . 3 . Known hypersensitivity intolerance study medication 4 . Not expect survive &gt; 1 week . 5 . Weight &lt; 4.5 kg ( blood volume draw limitation )</criteria>
	<gender>All</gender>
	<minimum_age>N/A</minimum_age>
	<maximum_age>18 Years</maximum_age>
	<verification_date>August 2016</verification_date>
	<keyword>Voriconazole</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Ontogeny</keyword>
	<keyword>Modeling</keyword>
	<keyword>Bayesian</keyword>
</DOC>